Javlor

Vinflunine, the active ingredient in Javlor, is a Vinca alkaloid presented as a sterile solution for injection for intravenous use. It is indicated for the treatment of advanced or metastatic urothelial carcinoma in adult patients who have progressed after prior platinum‑based chemotherapy, offering an option when standard regimens have failed. The drug is marketed in the European Union and conforms to international quality standards.

GNH USA supplies Javlor as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals, specialty pharmacies and clinics worldwide.

Javlor (vinflunine) is used in the management of urothelial carcinoma, a cancer of the urinary tract.

Advanced urothelial carcinoma (bladder): provides a treatment option after failure of platinum‑based chemotherapy. Advanced urothelial carcinoma (ureter): offers therapeutic benefit when disease progresses following standard regimens. Advanced urothelial carcinoma (renal pelvis): used as a later‑line therapy for patients with refractory disease.

Vinflunine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Neutropenia: reduced white blood cell count increasing infection risk. - Anemia: lowered red blood cells causing fatigue. - Nausea and vomiting: gastrointestinal upset. - Constipation: decreased bowel movements. - Fatigue: general weakness and tiredness. - Alopecia: hair loss.

Serious or Rare Side Effects: - Severe neutropenia with febrile infection. - Hemorrhage or bleeding complications. - Cardiac toxicity such as arrhythmias. - Acute renal failure. - Anaphylactic or severe allergic reactions. - Thromboembolic events.

Vinflunine requires careful monitoring and specific safety measures before and during therapy.

Monitor blood counts: perform regular complete blood count tests to detect neutropenia or anemia. Assess renal function: evaluate serum creatinine and glomerular filtration rate prior to each dose. Check hepatic function: monitor liver enzymes for potential hepatotoxicity. Avoid use in active severe infection: postpone treatment until infection is controlled. Use caution in patients with cardiac disease: observe for signs of arrhythmia or ischemia. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Vinflunine can interact with other medicines, altering its safety or effectiveness.

Major Interactions (Avoid): - Concomitant Vinca alkaloids or other microtubule inhibitors: additive toxicity. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase vinflunine exposure. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce vinflunine effectiveness.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): increased bleeding risk, monitor INR. - Nephrotoxic agents (e.g., cisplatin, aminoglycosides): heightened renal toxicity, check renal parameters. - Other myelosuppressive drugs (e.g., cyclophosphamide): enhanced bone‑marrow suppression, observe blood counts.